NCT05275439 2026-03-18
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Phase 1 Terminated
Clinical Trials
51 trialsNCT03547115 2026-03-17
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Phase 1 Terminated
NCT03404193 2026-03-10
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04964505 2026-02-23
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
University of California, Davis
Phase 1 Terminated
NCT04160052 2026-02-12
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03926624 2026-01-22
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Delta-Fly Pharma, Inc.
Phase 3 Terminated
NCT04150029 2026-01-13
STIMULUS-AML1
Novartis
Phase 2 Terminated
NCT05799079 2026-01-09
Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
NCT05317936 2025-12-15
Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT05361057 2025-12-05
Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive AML Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Terminated
NCT05464836 2025-11-26
Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04937166 2025-11-10
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Kahr Medical
Phase 1 Terminated
NCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06563804 2025-10-14
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Servier
Phase 1/2 Terminated
NCT03940352 2025-10-10
HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)
Novartis
Phase 1 Terminated
NCT05155709 2025-10-10
A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy.
Novartis
Phase 1 Terminated
NCT04161885 2025-10-06
VIALE-T
AbbVie
Phase 3 Terminated
NCT05168202 2025-09-25
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bristol-Myers Squibb
Phase 1 Terminated
NCT06508489 2025-08-22
A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies
Sanofi
Phase 1/2 Terminated
NCT06449482 2025-05-30
Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not Eligible for Intense Chemotherapy
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Terminated
NCT04752163 2025-05-23
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04435691 2025-04-27
Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT03492125 2025-04-10
A Study Of The Selective PKC-β Inhibitor MS- 553
MingSight Pharmaceuticals, Inc
Phase 1/2 Terminated
NCT05079230 2025-04-04
ENHANCE-3
Gilead Sciences
Phase 3 Terminated
NCT04553692 2025-03-28
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
IGM Biosciences, Inc.
Phase 1 Terminated
NCT04419389 2025-03-17
R/R
Aprea Therapeutics
Phase 1/2 Terminated
NCT04905407 2025-02-24
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Syros Pharmaceuticals
Phase 2 Terminated
NCT06150040 2025-02-20
AML-NET
Centre Leon Berard
Phase 1/2 Terminated
NCT04778397 2025-02-05
ENHANCE-2
Gilead Sciences
Phase 3 Terminated
NCT04029688 2024-12-20
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Hoffmann-La Roche
Phase 1/2 Terminated
NCT04755244 2024-11-27
A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)
ALX Oncology Inc.
Phase 1 Terminated
NCT03735875 2024-09-19
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04659044 2024-09-19
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Academic and Community Cancer Research United
Phase 2 Terminated
NCT03530683 2024-09-03
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Pfizer
Phase 1 Terminated
NCT03176277 2024-07-15
A Study of ONO-7475 in Patients With Acute Leukemias
Ono Pharmaceutical Co. Ltd
Phase 1/2 Terminated
NCT04336982 2024-05-31
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia
Celgene
Phase 1 Terminated
NCT03801525 2024-04-19
ULTRA-V
TG Therapeutics, Inc.
Phase 2/3 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04912063 2024-02-26
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
AbbVie
Phase 1 Terminated
NCT05107856 2024-01-31
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Prelude Therapeutics
Phase 1 Terminated
NCT04092179 2024-01-24
ENAVEN-AML
University Health Network, Toronto
Phase 1/2 Terminated
NCT04016805 2023-07-24
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax
TG Therapeutics, Inc.
Phase 2 Terminated
NCT03634228 2023-06-15
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02203773 2023-05-16
Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)
AbbVie
Phase 1 Terminated
NCT04748848 2023-03-02
A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy
Celgene
Phase 1 Terminated
NCT03484520 2022-12-30
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
AbbVie
Phase 1 Terminated
NCT03379051 2022-08-22
Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL
TG Therapeutics, Inc.
Phase 1/2 Terminated
NCT03217838 2022-04-05
Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.
AstraZeneca
Phase 1 Terminated